The breakthrough of WPD’s solution is that WPD101a binds specifically to IL-13α2 receptors overexpressed on GBM cells.

Binding of WPD101a to IL-13Rα2 expressing tumor cells is followed by internalization of the formed complex and intracellular release of cytotoxic DT via proteolytic cleavage.

Within the cytosol, enzymatically active DT is translocated into the endoplasmic reticulum, where it inactivates eEF2, thus inhibiting protein synthesis and inducing cancerous cell death.

More at:

https://www.globenewswire.com/news-release/2020/07/28/2068542/0/en/WPD-Pharmaceuticals-Provides-Update-on-WPD101-a-Drug-Candidate-Targeting-GBM-Tumors.html